Evidence map›Paper›PMID 27632986›Full record

ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2018

Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model.

Katherine N Gharibian, Venkatesh L Murthy, Bruce A Mueller

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022
    Article
  2. Article
  3. Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018
    Review
  4. Regadenoson use for stress myocardial perfusion imaging in advance chronic kidney disease and dialysis: Safe, effective, and efficient.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018
    Article
  5. Stress SPECT Myocardial Perfusion Imaging in End-Stage Renal Disease.Current cardiovascular imaging reports · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Katherine N GharibianSchool of Pharmacy, Medical College of Wisconsin, Milwaukee, WI, USA.
Venkatesh L MurthyDepartments of Internal Medicine and Radiology, Medical School, University of Michigan, Ann Arbor, MI, USA.
Bruce A MuellerDepartment of Clinical Pharmacy, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, MI, 48109, USA. muellerb@med.umich.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRegadenoson is a novel pharmacological stress agent whose disposition during hemodialysis is not known. The purpose of this study was to determine the clearance of regadenoson under varying dialytic conditions using an in vitro hemodialysis model. METHODS AND

resultsWhole human blood was used to analyze the effect of hemodialysis on the clearance of regadenoson. Regadenoson transmembrane clearance (CL

conclusionsHemodialysis enhances the clearance of regadenoson independent of hemodialyzer permeability and blood/dialysate flow rate. This clearance is modest relative to total body clearance and is unlikely to produce a clinically significant outcome.

Indexed as

Adenosine A2 Receptor AgonistsCreatinineHumansIn Vitro TechniquesPermeabilityPolymersPrognosisPurinesPyrazolesRenal DialysisSulfonesUreaAdenosine A2 Receptor AgonistsCreatininePolymerspolysulfone P 1700PurinesPyrazolesregadenosonSulfonesUreachronic kidney disease (CKD)clearancehemodialysisRegadenoson

Identifiers

PMID27632986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.